Common name
N-butylformamide
IUPAC name
N-butylformamide
SMILES
CCCCNC=O
Common name
N-butylformamide
IUPAC name
N-butylformamide
SMILES
CCCCNC=O
INCHI
InChI=1S/C5H11NO/c1-2-3-4-6-5-7/h5H,2-4H2,1H3,(H,6,7)
FORMULA
C5H11NO
Common name
N-butylformamide
IUPAC name
N-butylformamide
Molecular weight
101.147
clogP
0.506
clogS
-1.405
Frequency
0.0017
HBond Acceptor
1
HBond Donor
1
Total PolarSurface Area
29.1
Number of Rings
0
Rotatable Bond
3
| Drug ID | Common name | Structure CAS | Compound class | Therapeutic area |
|---|---|---|---|---|
| FDBD00753 | Benzylpenicilloyl Polylysine |
|
Acetamides; | For use as a adjunct in assessing the risk of administering penicillin (benzylpenicillin or penicillin G). |
| FDBD01369 | Telaprevir |
|
Protease Inhibitors; Antiinfectives for Systemic Use; Direct Acting Antivirals; Antivirals for Systemic Use; CYP3A4 Inhibitors; | Treating chronic hepatitis C virus (genotype 1) infection in patients with compensated liver (due to liver diseases like cirrhosis) that are treatment naive or have failed therapy with interferons (either null or partial responders and treatment relapsers). |
| FDBD01652 | Cobicistat |
|
Anti-HIV Agents; Antiinfectives for Systemic Use; Direct Acting Antivirals; Antivirals for Systemic Use; Cytochrome P-450 CYP3A Inhibitors; CYP2D6 Inducers; CYP2D6 Inducers (strong); | Cobicistat is a CYP3A inhibitor indicated to increase systemic exposure of atazanavir or darunavir (once daily dosing regimen) in combination with other antiretroviral agents in the treatment of HIV-1 infection. It is not interchangeable with ritonavir to increase systemic exposure of darunavir 600 mg twice daily, fosamprenavir, saquinavir, or tipranavir due to lack of exposure data. The use of cobicistat is not recommended with darunavir 600 mg twice daily, fosamprenavir, saquinavir or tipranavir. Complex or unknown mechanisms of drug interactions preclude extrapolation of ritonavir drug interactions to certain cobicistat interactions. Cobicistat and ritonavir when administered with either atazanavir or darunavir may result in different drug interactions when used with concomitant medications. |
| FDBD01789 | Sacubitril |
|
Cardiovascular System; Agents Acting on the Renin-Angiotensin System; | Used in combination with valsartan to reduce the risk of cardiovascular events in patients with chronic heart failure (NYHA Class II-IV). |
| FDBD03036 | iodocarb |
|
Fungicide | Fungicide |
5 ,
1
| FRAGNAME | PDBID | SIMILIRITY | XSCORE | SMILE | HAC |
|---|---|---|---|---|---|
| 1b3g_ligand_3_308.mol2 | 1b3g | 1 | -6.49 | C(C)[C@H](C)CNC=O | 8 |
| 1b9j_ligand_3_281.mol2 | 1b9j | 1 | -6.46 | C(CC(C)C)NC=O | 8 |
| 2v12_ligand_4_2565.mol2 | 2v12 | 1 | -6.40 | C(C)(C)[C@H](C)CNC=O | 9 |
| 3duy_ligand_3_710.mol2 | 3duy | 1 | -6.39 | C(=O)NCCC(C)C | 8 |
| 2p4j_ligand_3_396.mol2 | 2p4j | 1 | -6.34 | C(C(C)C)CNC=O | 8 |
| 3d3x_ligand_3_34.mol2 | 3d3x | 1 | -6.34 | [C@H](C)(CC)CNC=O | 8 |
| 4trw_ligand_3_914.mol2 | 4trw | 1 | -6.34 | C(=O)NCCC(C)C | 8 |
| 2hob_ligand_3_516.mol2 | 2hob | 1 | -6.33 | C(NC=O)CC(C)C | 8 |
352 ,
36
